TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gilead Sciences ( (GILD) ) has provided an update.
On November 19, 2025, Gilead Sciences announced that Deborah H. Telman will step down from her role as Executive Vice President, Corporate Affairs and General Counsel, effective December 5, 2025, with her employment terminating later in the month. This leadership change could impact Gilead’s corporate affairs strategy and legal operations, potentially influencing its industry positioning and stakeholder relations.
The most recent analyst rating on (GILD) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Gilead Sciences stock, see the GILD Stock Forecast page.
Spark’s Take on GILD Stock
According to Spark, TipRanks’ AI Analyst, GILD is a Outperform.
Gilead Sciences’ strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust profitability, effective cash flow management, and strategic advancements in its HIV portfolio contribute significantly to its attractiveness. Technical indicators support a generally positive outlook, though some caution is warranted due to potential overbought conditions. The valuation is fair, making the stock appealing for both growth and income investors.
To see Spark’s full report on GILD stock, click here.
More about Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines, primarily in the areas of antiviral and liver disease treatments.
Average Trading Volume: 7,035,669
Technical Sentiment Signal: Buy
Current Market Cap: $154B
See more data about GILD stock on TipRanks’ Stock Analysis page.